Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

Anna Dodero, MD, Anna Guidetti, MD, Fabrizio Marino, MD, Cristiana Carniti, PhD, Stefania Banfi, Alessandra Tucci, MD, Monica Balzarotti, Antonello Domenico Cabras, MD, Valentina Monti, PhD, Liliana Franca Devizzi, MD, Lucia Farina, MD, Maria Chiara Di Chio, MD, Giuseppe Rossi, Carmelo Carlo-Stella, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 4116.

https://doi.org/10.1182/blood-2019-124350

Published: 2019

Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 5619.

https://doi.org/10.1182/blood-2019-125286

Published: 2019

Journal Articles

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Annalisa Chiappella, MD, Cristiana Carniti, Andrea Evangelista, PhD, Maria Giuseppina Cabras, MD, Alessandro Re, MD, Manuela Zanni, MD, Vittorio Stefoni, Armando Santoro, MD, Angela Giovanna Congiu, Anna Dodero, MD, Stefano A. Pileri, MD PhD, Giovannino Ciccone, MD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2018-99-119763

Published: 2018

Journal Articles

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

Francesco Maura, Niccolò Bolli, Daniel Leongamornlert, BS, Cristiana Carniti, Anna Dodero, MD, Federico Abascal, Adele Testi, Bernardo Rodriguez-Martin, Alessio Pellegrinelli, Giulia Biancon, Martina Magni, Annalisa Chiappella, MD, Inigo Martincorena, Jose M. C. Tubio, Giancarlo Pruneri, Peter J. Campbell, PhD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2018-99-112094

Published: 2018

Journal Articles

Intention-to-Treat Analysis of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Non-Hodgkin Lymphomas: A Large Italian Single-Center Experience

Nicoletta Cieri, MD PhD, Anna Dodero, MD, Martina Pennisi, MD, Alberto Mussetti, MD, Lucia Farina, Anna Guidetti, MD, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 3322.

https://doi.org/10.1182/blood.V130.Suppl_1.3322.3322

Published: 2017

Journal Articles

A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes

Blood (2017) 130 (Supplement 1): 3997.

https://doi.org/10.1182/blood.V130.Suppl_1.3997.3997

Published: 2017

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Alessandra Tucci, MD, Anna Guidetti, MD, Anna Dodero, MD, Francesca Schieppati, MD, Alessandro Re, MD, Nicola Bianchetti, MD, Chiara Bottelli, MD, Angela Passi, MD, Maria Miscio, Simona Fisogni, MD, Piera Balzarini, Fabio Facchetti, MD, Paolo Corradini, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4154.

https://doi.org/10.1182/blood.V130.Suppl_1.4154.4154

Published: 2017

Journal Articles

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Anna Dodero, MD, Anna Guidetti, MD, Alessandra Tucci, MD, Alessio Pellegrinelli, Antonello Cabras, MD, Liliana Franca Devizzi, MD, Lucia Farina, Luca Pappalettera, MD, Alberto Mussetti, MD, Maria Chiara Di Chio, MD, Rosa Jessica, MD, Martina Soldarini, MD, Angela Passi, MD, Paola Matteucci, MD, Stefano A. Pileri, Giuseppe Rossi, MD, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 2844.

https://doi.org/10.1182/blood.V130.Suppl_1.2844.2844

Published: 2017

Journal Articles

Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes

Francesco Spina, MD, Serena Camilla Dalto, MD, Simonetta Viviani, MD, Chiara De Philippis, MD, Anna Dodero, MD, Lucia Farina, MD PhD, Vittorio Montefusco, Paolo Corradini, MD

Blood (2015) 126 (23): 2016.

https://doi.org/10.1182/blood.V126.23.2016.2016

Published: 2015

Journal Articles

GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes

Anna Dodero, MD, Francesco Maura, MD, Alessio Pellegrinelli, MD, Antonello Cabras, MD, Annalisa Chiappella, MD, Domenico Novero, MD, Federico Vittone, MD, Francesco Zaja, MD, Stefano Pizzolitto, MD, Cristiana Carniti, PhD, Alessandra Cavane', Martina Pennisi, MD, Umberto Vitolo, MD, Niccolo' Bolli, MD, Paolo Corradini

Blood (2015) 126 (23): 3889.

https://doi.org/10.1182/blood.V126.23.3889.3889

Published: 2015

Journal Articles

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Blood (2015) 126 (23): 3937.

https://doi.org/10.1182/blood.V126.23.3937.3937

Published: 2015

Journal Articles

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Anna Guidetti, MD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, Domenico Russo, MD PhD, Pietro Bulian, Massimo Di Nicola, MD, Arabella Mazzocchi, MD, Fernando Ravagnani, MD, Paolo Corradini, MD, Alessandro Massimo Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4459.

https://doi.org/10.1182/blood.V124.21.4459.4459

Published: 2014

Journal Articles

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Simonetta Viviani, MD, Serena Dalto, MD, Paola Matteucci, MD, Massimo Di Nicola, MD, Anna Guidetti, MD, Liliana Devizzi, MD, Michele Magni, MD, Anna Dodero, MD, Lucia Farina, MD, Francesco Spina, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 5428.

https://doi.org/10.1182/blood.V124.21.5428.5428

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse

Anna Dodero, MD, Francesco Spina, MD, Franco Narni, Francesca Patriarca, MD, Fabio Benedetti, MD, Donatella Baronciani, MD, Alessandro Rambaldi, Attilio Olivieri, MD, Serena Dalto, MD, Benedetto Bruno, MD, Umberto Vitolo, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 2574.

https://doi.org/10.1182/blood.V124.21.2574.2574

Published: 2014

Journal Articles

High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect

Anna Dodero, MD, Francesco Spina, MD PhD, Barbara Sarina, MD, Cristiana Carniti, Francesca Patriarca, MD, Angelo Michele Carella, Alessandro Levis, Alberto Bosi, MD, Michele Falda, MD, Paolo Di Bartolomeo, MD, Francesco Onida, MD, Serena Dalto, MD, Antonio Vendramin, Alessandro Rambaldi, MD, Paolo Corradini

Blood (2013) 122 (21): 2059.

https://doi.org/10.1182/blood.V122.21.2059.2059

Published: 2013

Journal Articles

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Blood (2012) 120 (21): 1984.

https://doi.org/10.1182/blood.V120.21.1984.1984

Published: 2012

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

Blood (2012) 120 (21): 550.

https://doi.org/10.1182/blood.V120.21.550.550

Published: 2012

Journal Articles

High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas

Paolo Corradini, Barbara Sarina, MD, Cristiana Carniti, PhD, Francesca Patriarca, MD, Angelo Michele Carella, MD, Alessandro Levis, Alberto Bosi, MD, Michele Falda, Paolo Di Bartolomeo, MD, Cecilia Olivares, MD, Silvia Gimondi, Antonio Vendramin, Anna Dodero, MD

Blood (2011) 118 (21): 4546.

https://doi.org/10.1182/blood.V118.21.4546.4546

Published: 2011

NARROW

Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified

Intention-to-Treat Analysis of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Non-Hodgkin Lymphomas: A Large Italian Single-Center Experience

A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes

GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse

High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only